Activated proteine C;La protéine C activée

Annales Francaises d'Anesthesie et de Reanimation

Volumn 25, Issue 3, 2006, Pages 270-274

  Montravers, P ^a,b   Quintard, H ^a   Piednoir, P ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL JEAN VERDIER   (France)

Author keywords

Coagulation; Drotrecogin alfa activated; Protein C; Septic shock; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; RECOMBINANT PROTEIN; THROMBIN;

APOPTOSIS; BLOOD CLOTTING DISORDER; CLINICAL STUDY; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INHIBITION; DRUG USE; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; MORTALITY; OPEN STUDY; PRACTICE GUIDELINE; PUBLICATION; REVIEW; SEPSIS; THROMBOSIS;

EID: 33645528409     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2005.10.006     Document Type: Article

References (24)

1. R.P. Dellinger, J.M. Carlet, H. Masur, H. Gerlach, T. Calandra, and J. Cohen Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock Crit. Care Med. 32 2004 858 873
2. F.B. Taylor, A. Chang, C.T. Esmon, A. D'Angelo, S. Vigano-D'Angelo, and K.E. Blick Protein C prevents the coagulopathic and lethal effects of Escherichia:coli infusion in the baboon J. Clin. Invest. 79 1987 918 925
3. F. Fourrier, C. Chopin, J. Goudemand, S. Hendrycx, C. Caron, and A. Rime Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies Chest 101 1992 816 823
4. J.A. Lorente, L.J. Garcia-Frade, L. Landin, R. de Pablo, C. Torrado, and E. Renes Time course of hemostatic abnormalities in sepsis and its relation to outcome Chest 103 1993 1536 1542
5. J. Boldt, M. Papsdorf, A. Rothe, B. Kumle, and S. Piper Changes of the hemostatic network in critically ill patients - is there a difference between sepsis, trauma, and neurosurgery patients? Crit. Care Med. 28 2000 445 450
6. W.T. Gerson, J.D. Dickerman, E.G. Bovill, and E. Golden Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate Pediatrics 91 1993 418 422
7. E. Rintala, O.P. Seppala, P. Kotilainen, V. Pettila, and V. Rasi Protein C in the treatment of coagulopathy in meningococcal disease Crit. Care Med. 26 1998 965 968
8. G.E. Rivard, M. David, C. Farrell, and H.P. Schwarz Treatment of purpura fulminans in meningococcemia with protein C concentrate J. Pediatr. 126 1995 646 652
9. O.P. Smith, B. White, D. Vaughan, M. Rafferty, L. Claffey, and B. Lyons Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans Lancet 350 1997 1590 1593
10. G.R. Bernard, E.W. Ely, T.J. Wright, J. Fraiz, J.E. Stasek Jr., and J.A. Russell Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis Crit. Care Med. 29 2001 2051 2059
11. S.C. Yan, P. Razzano, Y.B. Chao, J.D. Walls, D.T. Berg, and D.B. McClure Characterization and novel purification of recombinant human protein C from three mammalian cell lines Biotechnology (N. Y.) 8 1990 655 661
12. G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, and A. Lopez-Rodriguez Efficacy and safety of recombinant human activated protein C for severe sepsis N. Engl. J. Med. 344 2001 699 709
13. D.C. Angus, P.F. Laterre, J. Helterbrand, E.W. Ely, D.E. Ball, and R. Garg The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis Crit. Care Med. 32 2004 2199 2206
14. J.F. Dhainaut, P.F. Laterre, S.P. LaRosa, H. Levy, G.E. Garber, and D. Heiselman The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results Crit. Care Med. 31 2003 2291 2301
15. J.F. Dhainaut, P.F. Laterre, J.M. Janes, G.R. Bernard, A. Artigas, and J. Bakker Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial Intensive Care Med. 29 2003 894 903
16. J.L. Vincent, D.C. Angus, A. Artigas, A. Kalil, B.R. Basson, and H.H. Jamal Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial Crit. Care Med. 31 2003 834 840
17. E.W. Ely, P.F. Laterre, D.C. Angus, J.D. Helterbrand, H. Levy, and J.F. Dhainaut Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis Crit. Care Med. 31 2003 12 19
18. S.M. Opal, G.E. Garber, S.P. LaRosa, D.G. Maki, R.C. Freebairn, and G.T. Kinasewitz Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated) Clin. Infect. Dis. 37 2003 50 58
19. E.W. Ely, D.C. Angus, M.D. Williams, B. Bates, R. Qualy, and G.R. Bernard Drotrecogin alfa (activated) treatment of older patients with severe sepsis Clin. Infect. Dis. 37 2003 187 195
20. P.S. Barie, M.D. Williams, J.S. McCollam, B.M. Bates, R.L. Qualy, and S.F. Lowry Benefit-risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis Am. J. Surg. 188 2004 212 220
21. G.R. Bernard, B.D. Margolis, H.M. Shanies, E.W. Ely, A.P. Wheeler, and H. Levy Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis Chest 125 2004 2206 2216
22. P.Q. Eichacker, and C. Natanson Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials Crit. Care Med. 31 2003 S94 S96
23. E.D. de Kleijn, R. de Groot, C.E. Hack, P.G. Mulder, W. Engl, and B. Moritz Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study Crit. Care Med. 31 2003 1839 1847
24. B.L. Davidson, W.H. Geerts, and A.W. Lensing Low-dose heparin for severe sepsis N. Engl. J. Med. 347 2002 1036 1037